Twitter

Archive for October 19th, 2011


BRCA Gene Mutations May Influence Survival, Treatment Response in Ovarian Cancer

Women with ovarian cancer who have a mutated form of the BRCA2 gene may be more likely to respond to standard chemotherapy and have better overall and progression-free survival than women without the mutation, according to a new study published October 12 in JAMA. The findings also suggested that women with BRCA1 mutations had better overall and progression-free survival than women whose tumors lacked the mutations, but these latter findings were not statistically significant.

Read More...

Charles V. Long Jr.

… away peacefully Monday, Oct. 17, 2011, at his home after a short battle with leukemia. He was born June 8, 1923, to Helen E. and Charles V. Long Sr. …

Read More...

Aflac Renews Commitment to Cancer Treatment and Research

… Aflac, has shown that adolescents and young adult (AYA) patients treated for acute myeloid leukemia are more than twice as likely to die of treatment-related causes as are younger …

Read More...

Higher-Dose Radiation Does Not Improve Survival in Some Lung Cancer Patients

A higher dose of radiation therapy does not improve survival in patients with stage III non-small cell lung cancer (NSCLC) who are not candidates for surgery, researchers reported last week. The findings come from an interim analysis of a phase III randomized clinical trial presented at the American Society for Radiation Oncology (ASTRO) annual meeting in Miami.

Read More...

Women’s gift brings joy to boy facing serious challenge

… SETH Mason was diagnosed with T-cell acute lymphoblastic leukaemia last year. And his battle recently touched the hearts of the women at the …

Read More...

Nonanthracycline Chemotherapy May Be an Option for Some Women with HER2-Positive Breast Cancer

A nonanthracycline-containing chemotherapy regimen combined with the targeted therapy trastuzumab (Herceptin) may be an option for some women with HER2-positive breast cancer, according to results from the Breast Cancer International Research Group 006 (BCIRG-006) trial. The investigators showed that the combined regimen was superior to the standard anthracycline and taxane-based regimen. These results, the first from a large randomized breast cancer trial to test nonanthracycline chemotherapy with trastuzumab, were reported online October 6 in the New England Journal of Medicine.

Read More...

Front Porch: Barbecue fundraiser to aid Mill Creek boy with leukemia

… Front Porch: Barbecue fundraiser to aid Mill Creek boy with leukemia A barbecue fundraiser, “Come out for Colton,” is planned Saturday in Mill Creek. It’s …

Read More...

35-year-old recovers from diagnosis of acute leukemia, stroke

Read More...

"Michele Bachmann" helps expose Gardasil Cervical Cancer Scam

Women, girls BEWARE! do not take the vaccine, the inoculation, the bad medicine…

Read More...

ESGO 2011: Immunotherapy developments in cervical cancer

Prof Hans Nijman discusses the future of immunotherapy in cervical cancer and how he believes that this is where the future of cancer treatment is going. Prof Nijman believes that the current prophylactic vaccines, such as the HPV vaccine, will lead to the development of therapeutic vaccines. The ultimate goal for immunotherapy is to educate the immune system so that it identifies tumour cells as non-self. Whether or not vaccines will be developed for other types of cancer is a question of time. Dr Nijman notes that the traditional treatments of chemotherapy and radiation are not as effective if the immune system does not act as is intended. Once more vaccines are produced; the next goal will be to create specific treatments for each particular patient by harnessing their immune system. www.ecancermedicalscience.com

Read More...